Physician profile
Gerry Ovide
NPI 1235621749
$29,309.00
in general payments reported to CMS, 2019-2025
9 companies · $29K in 2025
The $29K reported for 2025 was more than what 99% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $8.57 · 2022: $18.89 · 2023: $26.80 · 2024: $395 · 2025: $29K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Grant: $23K · Food and Beverage: $3,862 · Travel and Lodging: $2,415 · Education: $505.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Grant | $22,500.00 |
| Food and Beverage | $3,862.31 |
| Travel and Lodging | $2,414.50 |
| Education | $504.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $22,897.84 | 2025 | Assurity, Tacticath, Ensite |
| Boston Scientific Corporation | $3,475.65 | 2022-2025 | General - Therapies |
| Medtronic, INC. | $1,532.32 | 2025 | Cobalt Dr Mri Surescan |
| Biotronik INC. | $842.59 | 2025 | Acticor 7 Vr-T Dx |
| Irhythm Technologies, INC. | $232.95 | 2024 | Zio Monitor, Zio Xt Patch |
| Abiomed | $138.50 | 2024 | Impella |
| Amgen INC. | $130.08 | 2025 | Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $35.37 | 2021-2023 | Lifevest |
| Novo Nordisk INC | $23.70 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gerry Ovide listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.